Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness, as opposed to treatments that generally sedate the brain
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Prior to IHH, Anurag held senior leadership roles in Fortis Healthcare and Manipal Health Enterprises.
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
The stability is led by healthy demand in the domestic and emerging markets
The study will be published on the pre-print server, medRXiv, shortly
Subscribe To Our Newsletter & Stay Updated
